Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial

The purpose of this study was to determine the prognostic significance and associated clinical profile of early post‐discharge N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) trajectory among patients hospitalized for worsening chronic heart failure (HHF).

[1]  L. Allen,et al.  Critical elements of clinical follow‐up after hospital discharge for heart failure: insights from the EVEREST trial , 2010, European journal of heart failure.

[2]  I. V. Van Gelder,et al.  Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  Robert O. Bonow,et al.  Rehospitalization for heart failure: problems and perspectives. , 2013, Journal of the American College of Cardiology.

[4]  D. Lloyd‐Jones,et al.  Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2007, American heart journal.

[5]  J. Januzzi,et al.  Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. , 2013, Circulation.

[6]  G. Filippatos,et al.  Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. , 2006, The American journal of medicine.

[7]  Pedro Lozano.  Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.

[8]  M. Gheorghiade,et al.  Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) , 2011, European journal of heart failure.

[9]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[10]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[11]  K. Swedberg,et al.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.

[12]  Gianni Tognoni,et al.  Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.

[13]  J. Cohn,et al.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. , 2006, Clinical chemistry.

[14]  J. Januzzi.  Natriuretic Peptides as Biomarkers in Heart Failure , 2013, Journal of Investigative Medicine.

[15]  S. Solomon,et al.  Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. , 2013, JAMA.

[16]  Kevin J. Anstrom,et al.  Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. , 2014, JACC. Heart failure.

[17]  Y. Kihara,et al.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. , 2006, Journal of the American College of Cardiology.

[18]  Shawn A. Gregory,et al.  Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. , 2011, Journal of the American College of Cardiology.

[19]  A. Maisel,et al.  State-of-the-Art PaperNatriuretic Peptides , 2007 .

[20]  V. Hasselblad,et al.  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. , 2009, American heart journal.

[21]  J. Cohn,et al.  Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. , 2006, The American journal of medicine.

[22]  G. Filippatos,et al.  Haemoconcentration, renal function, and post‐discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial , 2013, European journal of heart failure.

[23]  L. Allen,et al.  Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life , 2011, Circulation. Cardiovascular quality and outcomes.

[24]  S. Kimmel,et al.  Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and Survival , 2010, Circulation.

[25]  W. Kop,et al.  Post-discharge changes in NT-proBNP and quality of life after acute dyspnea hospitalization as predictors of one-year outcomes. , 2010, Clinical biochemistry.

[26]  D. Brotman,et al.  Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. , 2011, The American journal of cardiology.

[27]  S. Solomon,et al.  Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. , 2013, European heart journal.

[28]  G. Filippatos,et al.  A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial , 2012, Heart Failure Reviews.

[29]  Eric M. Reyes,et al.  Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term OutcomesClinical Perspective , 2011 .

[30]  Gabriel Thabut,et al.  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.

[31]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[32]  P. Ponikowski,et al.  Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). , 2013, JACC. Heart failure.

[33]  Eric M. Reyes,et al.  Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes: Data From Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Linked to Medicare Claims , 2011, Circulation. Heart failure.

[34]  A. Bayés‐Genís,et al.  Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. , 2007, International journal of cardiology.

[35]  C. O'connor,et al.  Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. , 2012, American heart journal.